Consult the medical resource doctors trust

UpToDate is one of the most respected evidence-based medical information resources in the world, used by over 400,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Bone and joint complications in sickle cell disease

INTRODUCTION

Although sickle cell disease (SCD) is characterized by a marked heterogeneity in clinical and hematologic severity [1,2], bone and joint problems are the most common manifestations. Pain, caused by vaso-occlusive crises (VOC), may occur as often as every week or as rarely as once a year. Many patients also suffer from the long-term consequences of VOC, such as avascular necrosis of the femoral heads or collapsed vertebral bodies, leading to a chronic state of pain in addition to the more acute painful crises.

Bone and joint complications in SCD are discussed here [3]. Other manifestations of the disease are discussed separately. (See "Overview of the clinical manifestations of sickle cell disease".)

PATHOGENESIS

The interaction between sickle red cells and the vascular endothelium appears to be of great importance in the pathogenesis of crises, including the role of hemoglobin S polymerization and subsequent red cell distortion, interaction of sickle cells with adhesion proteins of the vascular endothelium, as well as the ensuing inflammatory response, which further increases cellular adhesiveness [4-8]. (See "Vasoocclusion in sickle cell disease".)

Sickle erythrocytes can upregulate gene expression of the intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in vascular endothelial cells in vitro, and certain drugs (eg, sulfasalazine) have been evaluated with regard to their effect on adhesion [9,10]. Heme and heme oxygenase, the heme-degrading enzyme, also are potent inducers of inflammation and endothelial cell adhesion [11], as is exposure of phosphatidylserine on the surface of the red cell [12].

Increased adhesion and subsequent inflammatory response decrease blood flow, leading to further sickling in an increasingly hypoxic and acidic environment, manifested by the typical pain associated with vaso-occlusive crises. Repeated episodes of decreased blood flow can lead to impaired nourishment of critical structures (eg, femoral head or vertebral bodies), leading to bony lesions with loss of trabeculae (eg, avascular necrosis, vertebral collapse).

» To continue reading this article you need to login or subscribe.

Ready to join over 400,000 satisfied users? Subscribe to read this article and others like it.
Last literature review version 18.2: May 2010
This topic last updated: July 2, 2009
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2010 UpToDate, Inc.
References
Top
  1. Platt, OS, Thorington, BD, Brambilla, DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.
  2. Platt, OS. Easing the suffering caused by sickle cell disease. N Engl J Med 1994; 330:783.
  3. Almeida, A, Roberts, I. Bone involvement in sickle cell disease. Br J Haematol 2005; 129:482.
  4. Graido-Gonzalez, E, Doherty, JC, Bergreen, EW, et al. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 1998; 92:2551.
  5. Belcher, JD, Marker, PH, Weber, JP, Hebbel, RP, Vercellotti, GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000; 96:2451.
  6. Hebbel, RP, Vercellotti, GM. The endothelial biology of sickle cell disease. J Lab Clin Med 1997; 129:288.
  7. Fadlon, E, Vordermeier, S, Pearson, TC, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 1998; 91:266.
  8. Bunn, HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337:762.
  9. Shiu, YT, Udden, MM, McIntire, LV. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 2000; 95:3232.
  10. Solovey, AA, Solovey, AN, Harkness, J, Hebbel, RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 2001; 97:1937.
  11. Wagener, FA, Eggert, A, Boerman, OC, et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 2001; 98:1802.
  12. Setty, BN, Kulkarni, S, Stuart, MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood 2002; 99:1564.
  13. Ware, MA, Hambleton, I, Ochaya, I, Serjeant, GR. Day-care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere?. Br J Haematol 1999; 104:93.
  14. Michaels, LA, Ohene-Frempong, K, Zhao, H, Douglas, SD. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood 1998; 92:3148.
  15. Mollapour, E, Porter, JB, Kaczmarski, R, et al. Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease. Blood 1998; 91:3423.
  16. Barbeau, P, Woods, KF, Ramsey, LT, et al. Exercise in sickle cell anemia: effect on inflammatory and vasoactive mediators. Endothelium 2001; 8:147.
  17. Morris, CR, Kuypers, FA, Larkin, S, et al. Patterns of arginine and nitric oxide in sickle cell disease patients with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000; 22:515.
  18. Browne, PV, Mosher, DF, Steinberg, MH, Hebbel, RP. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 1996; 51:296.
  19. Brittain, HA, Eckman, JR, Swerlick, RA, et al. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood 1993; 81:2137.
  20. Wagener, FA, Abraham, NG, van Kooyk, Y, et al. Heme-induced cell adhesion in the pathogenesis of sickle-cell disease and inflammation. Trends Pharmacol Sci 2001; 22:52.
  21. Patel, RP. Biochemical aspects of the reaction of hemoglobin and NO: implications for Hb-based blood substitutes. Free Radic Biol Med 2000;28:1518.
  22. Reiter, CD, Wang, X, Tanus-Santos, JE, Hogg, N. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383.
  23. Petrovic, P, Kalso, E, Petersson, KM, Ingvar, M. Placebo and opioid analgesia-- imaging a shared neuronal network. Science 2002; 295:1737.
  24. Keeley, K, Buchanan, GR. Acute infarction of long bones in children with sickle cell anemia. J Pediatr 1982; 101:170.
  25. Resar, LM, Oliva, MM, Casella, JF. Skull infarction and epidural hematomas in a patient with sickle cell anemia. J Pediatr Hematol Oncol 1996; 18:413.
  26. Gelfand, MJ, Daya, SA, Rucknagel, DL, Kalinyak, KA, Paltiel, HJ. Simultaneous occurrence of rib infarction and pulmonary infiltrates in sickle cell disease patients with acute chest syndrome. J Nucl Med 1993; 34:614.
  27. Roger, E, Letts, M. Sickle cell disease of the spine in children. Can J Surg 1999; 42:289.
  28. Rao, SP, Miller, S, Solomon, N. Acute bone and joint manifestations of sickle cell disease in children. N Y State J Med 1986; 86:254.
  29. Alavi, A, Heyman, S, Kim, HC. Scintigraphic examination of bone and marrow infarcts in sickle cell disorders. Semin Roentgenol 1987; 22:213.
  30. Rao, S, Solomon, N, Miller, S, Dunn, E. Scintigraphic differentiation of bone infarction from osteomyelitis in children with sickle cell disease. J Pediatr 1985; 107:685.
  31. Skaggs, DL, Kim, SK, Greene, NW, et al. Differentiation between bone infarction and acute osteomyelitis in children with sickle-cell disease with use of sequential radionuclide bone-marrow and bone scans. J Bone Joint Surg Am 2001; 83-A:1810.
  32. Mankad, VN, Williams, JP, Harpen, MD, et al. Magnetic resonance imaging of bone marrow in sickle cell disease: clinical, hematologic, and pathologic correlations. Blood 1990; 75:274.
  33. Shapiro, BS, Dinges, DF, Orne, EC, et al. Home management of sickle cell-related pain in children and adolescents: natural history and impact on school attendance. Pain 1995; 61:139.
  34. Health supervision for children with sickle cell disease. Pediatrics 2002; 109:526.
  35. Jacob, E. Pain management in sickle cell disease. Pain Manag Nurs 2001; 2:121.
  36. Benjamin, LJ, Swinson, GI, Nagel, RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood 2000; 95:1130.
  37. Bellet, PS, Kalinyak, KA, Shukla, R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995; 333:699.
  38. Bernini, JC, Rogers, ZR, Sandler, ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92:3082.
  39. Miller, ST, Wright, E, Abboud, M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001; 139:785.
  40. Pegelow, CH. Survey of pain management therapy provided for children with sickle cell disease. Clin Pediatr (Phila) 1992; 31:211.
  41. Charache, S, Terrin, ML, Moore, RD, et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332:1317.
  42. Scott, JP, Hillery, CA, Brown, ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996; 128:820.
  43. Miller, MK, Zimmerman, SA, Schultz, WH, Ware, RE. Hydroxyurea therapy for pediatric patients with hemoglobin SC disease. J Pediatr Hematol Oncol 2001; 23:306.
  44. Charache, S, Terrin, ML, Moore, RD, et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. Control Clin Trials 1995; 16:432.
  45. Kinney, TR, Helms, RW, O'Branski, EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999; 94:1550.
  46. Ferster, A, Tahrir, P, Vermylen, C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001; 97:3628.
  47. Claster, S, Vichinsky, E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: Splenic regeneration. Blood 1996; 88:1951.
  48. Gill, FM, Sleeper, LA, Weiner, SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995; 86:776.
  49. Stevens, MC, Padwick, M, Serjeant, GR. Observations on the natural history of dactylitis in homozygous sickle cell disease. Clin Pediatr (Phila) 1981; 20:311.
  50. Miller, ST, Sleeper, LA, Pegelow, CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342:83.
  51. Bennett, OM. Salmonella osteomyelitis and the hand-foot syndrome in sickle cell disease. J Pediatr Orthop 1992; 12:534.
  52. Webb, DK, Serjeant, GR. Haemophilus influenzae osteomyelitis complicating dactylitis in homozygous sickle cell disease. Eur J Pediatr 1990; 149:613.
  53. Barrett-Connor, E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore) 1971; 50:97.
  54. Bennett, OM, Namnyak, SS. Bone and joint manifestations of sickle cell anaemia. J Bone Joint Surg [Br] 1990; 72:494.
  55. Anand, AJ, Glatt, AE. Salmonella osteomyelitis and arthritis in sickle cell disease. Semin Arthritis Rheum 1994; 24:211.
  56. Neonato, MG, Lu, CY, Guilloud-Bataille, M, et al. Genetic polymorphism of the mannose-binding protein gene in children with sickle cell disease: identification of three new variant alleles and relationship to infections. Eur J Hum Genet 1999; 7:679.
  57. Tamouza, R, Neonato, MG, Busson, M, et al. Infectious complications in sickle cell disease are influenced by HLA class II alleles. Hum Immunol 2002; 63:194.
  58. Chambers, JB, Forsythe, DA, Bertrand, SL, et al. Retrospective review of osteoarticular infections in a pediatric sickle cell age group. J Pediatr Orthop 2000; 20:682.
  59. Burnett, MW, Bass, JW, Cook, BA. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics 1998; 101:296.
  60. Hook, EW, Campbell, CG, Weens, HS, Cooper, GR. Salmonella osteomyelitis in patients with sickle-cell anemia. N Engl J Med 1957; 257:403.
  61. Syrogiannopoulos, GA, McCracken, GH Jr, Nelson, JD. Osteoarticular infections in children with sickle cell disease. Pediatrics 1986; 78:1090.
  62. Sadat-Ali, M. The status of acute osteomyelitis in sickle cell disease. A 15-year review. Int Surg 1998; 83:84.
  63. Sankaran-Kutty, M, Sadat-Ali, M, Kutty, MK. Septic arthritis in sickle cell disease. Int Orthop 1988; 12:255.
  64. Nistala, K, Murray, KJ. Co-existent sickle cell disease and juvenile rheumatoid arthritis. Two cases with delayed diagnosis and severe destructive arthropathy. J Rheumatol 2001; 28:2125.
  65. Berger, E, Saunders, N, Wang, L, Friedman, JN. Sickle cell disease in children: Differentiating osteomyelitis from vaso-occlusive crisis. Arch Pediatr Adolesc Med 2009; 163:251.
  66. Umans, H, Haramati, N, Flusser, G. The diagnostic role of gadolinium enhanced MRI in distinguishing between acute medullary bone infarct and osteomyelitis. Magn Reson Imaging 2000; 18:255.
  67. William, RR, Hussein, SS, Jeans, WD, et al. A prospective study of soft-tissue ultrasonography in sickle cell disease patients with suspected osteomyelitis. Clin Radiol 2000; 55:307.
  68. Rao, VM, Mitchell, DG, Rifkin, MD, et al. Marrow infarction in sickle cell anemia: correlation with marrow type and distribution by MRI. Magn Reson Imaging 1989; 7:39.
  69. Booz, MM, Hariharan, V, Aradi, AJ, Malki, AA. The value of ultrasound and aspiration in differentiating vaso-occlusive crisis and osteomyelitis in sickle cell disease patients. Clin Radiol 1999; 54:636.
  70. Milner, PF, Kraus, AP, Sebes, JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991; 325:1476.
  71. Hawker, H, Neilson, H, Hayes, RJ, Serjeant, GR. Haematological factors associated with avascular necrosis of the femoral head in homozygous sickle cell disease. Br J Haematol 1982; 50:29.
  72. Adekile, AD, Gupta, R, Yacoub, F, et al. Avascular necrosis of the hip in children with sickle cell disease and high Hb F: magnetic resonance imaging findings and influence of alpha-thalassemia trait. Acta Haematol 2001; 105:27.
  73. Milner, PF, Kraus, AP, Sebes, JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop 1993; :136.
  74. Hernigou, P, Galacteros, F, Bachir, D, Goutallier, D. Deformities of the hip in adults who have sickle-cell disease and had avascular necrosis in childhood. A natural history of fifty-two patients. J Bone Joint Surg Am 1991; 73:81.
  75. Hernigou, P, Habibi, A, Bachir, D, Galacteros, F. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg Am 2006; 88:2565.
  76. Mitchell, DG, Steinberg, ME, Dalinka, MK, et al. Magnetic resonance imaging of the ischemic hip. Alterations within the osteonecrotic, viable, and reactive zones. Clin Orthop 1989; :60.
  77. Huo, MH, Friedlaender, GE, Marsh, JS. Orthopaedic manifestations of sickle-cell disease. Yale J Biol Med 1990; 63:195.
  78. Mankin, HJ. Nontraumatic necrosis of bone. N Engl J Med 1992; 326:1473.
  79. Steinberg, ME. Early diagnosis of avascular necrosis of the femoral head. Instr Course Lect 1988; 37:51.
  80. Garino, JP, Steinberg, ME. Total hip arthroplasty in patients with avascular necrosis of the femoral head: a 2- to 10-year follow-up. Clin Orthop 1997; :108.
  81. Steinberg, ME. Classification of avascular necrosis: a comparative study. Acta Orthop Belg 1999; 65 Suppl 1:45.
  82. Vichinsky, EP, Neumayr, LD, Haberkern, C, et al. The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. Am J Hematol 1999; 62:129.
  83. Steinberg, ME. Core decompression of the femoral head for avascular necrosis: indications and results. Can J Surg 1995; 38 Suppl 1:S18.
  84. Styles, LA, Vichinsky, EP. Core decompression in avascular necrosis of the hip in sickle-cell disease. Am J Hematol 1996; 52:103.
  85. Castro, FP Jr, Barrack, RL. Core decompression and conservative treatment for avascular necrosis of the femoral head: a meta-analysis. Am J Orthop 2000; 29:187.
  86. Neumayr, LD, Aguilar, C, Earles, AN, et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am 2006; 88:2573.
  87. Curran, EL, Fleming, JC, Rice, K, Wang, WC. Orbital compression syndrome in sickle cell disease. Ophthalmology 1997; 104:1610.
  88. Ganesh, A, William, RR, Mitra, S, et al. Orbital involvement in sickle cell disease: a report of five cases and review literature. Eye 2001; 15:774.
  89. Naran, AD, Fontana, L. Sickle cell disease with orbital infarction and epidural hematoma. Pediatr Radiol 2001; 31:257.
  90. Royal, JE, Harris, VJ, Sansi, PK. Facial bone infarcts in sickle cell syndromes. Radiology 1988; 169:529.
  91. Ganesh, A, Al-Zuhaibi, S, Pathare, A, et al. Orbital infarction in sickle cell disease. Am J Ophthalmol 2008; 146:595.
  92. Platt, OS, Rosenstock, W, Espeland, MA. Influence of sickle hemoglobinopathies on growth and development. N Engl J Med 1984; 311:7.
  93. Luporini, SM, Bendit, I, Manhani, R, et al. Growth hormone and insulin-like growth factor I axis and growth of children with different sickle cell anemia haplotypes. J Pediatr Hematol Oncol 2001; 23:357.
  94. Soliman, AT, Bererhi, H, Darwish, A, et al. Decreased bone mineral density in prepubertal children with sickle cell disease: correlation with growth parameters, degree of siderosis and secretion of growth factors. J Trop Pediatr 1998; 44:194.
  95. Buison, AM, Kawchak, DA, Schall, JI, et al. Bone area and bone mineral content deficits in children with sickle cell disease. Pediatrics 2005; 116:943.
  96. Sarrai, M, Duroseau, H, D'Augustine, J, et al. Bone mass density in adults with sickle cell disease. Br J Haematol 2007; 136:666.
  97. Schumacher, HR, Andrews, R, McLaughlin, G. Arthropathy in sickle-cell disease. Ann Intern Med 1973; 78:203.
  98. Schumacher, HR, Dorwart, BB, Bond, J, et al. Chronic synovitis with early cartilage destruction in sickle cell disease. Ann Rheum Dis 1977; 36:413.
  99. Hanissian, AS, Silverman, A. Arthritis of sickle cell anemia. South Med J 1974; 67:28.
  100. Schuman, WB, Armstrong, FD, Pegelow, CH, Routh, DK. Enhanced parenting knowledge and skills in mothers of preschool children with sickle cell disease. J Pediatr Psychol 1993; 18:575.
  101. Fowler, MG, Johnson, MP, Atkinson, SS. School achievement and absence in children with chronic health conditions. J Pediatr 1985; 106:683.
  102. Graumlich, SE, Powers, SW, Byars, KC, et al. Multidimensional assessment of pain in pediatric sickle cell disease. J Pediatr Psychol 2001; 26:203.
  103. Maikler, VE, Broome, ME, Bailey, P, Lea, G. Childrens' and adolescents' use of diaries for sickle cell pain. J Soc Pediatr Nurs 2001; 6:161.
  104. Fuggle, P, Shand, PA, Gill, LJ, Davies, SC. Pain, quality of life, and coping in sickle cell disease. Arch Dis Child 1996; 75:199.
  105. Morrison, RA. Update on sickle cell disease: incidence of addiction and choice of opioid in pain management. Pediatr Nurs 1991; 17:503.
  106. Shapiro, BS, Benjamin, LJ, Payne, R, Heidrich, G. Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage 1997; 14:168.
  107. Pack-Mabien, A, Labbe, E, Herbert, D, Haynes, J Jr. Nurses' attitudes and practices in sickle cell pain management. Appl Nurs Res 2001; 14:187.
Bone and joint complications in sickle cell disease Diagnosis and management of placenta accreta Patient information: Type 2 diabetes mellitus and diet Patient information: Tamoxifen and raloxifene for the prevention of breast cancer Patient information: Helicobacter pylori infection and treatment Patient information: Gastroesophageal reflux disease in adults Patient information: Ulcerative colitis Patient information: Crohn's disease Patient information: Peptic ulcer disease Clinical manifestations and diagnosis of Kawasaki disease